- GlobeNewswire•14 days ago
ROCKVILLE, Md., Sept. 14, 2016-- Rexahn Pharmaceuticals, Inc. today announced it has entered into a definitive agreement with institutional investors to purchase 24 million shares of its common stock and ...
- GlobeNewswire•16 days agoRexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer
Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patients for Whom Three Prior Therapies had been Ineffective. RX-3117 was Safe and Well Tolerated. Results Have Been Submitted ...
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||0.21 x 1600|
|Ask||0.23 x 7300|
|Day's Range||0.22 - 0.23|
|52wk Range||0.20 - 0.54|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.45|
|Avg Vol (3m)||602,506|
|Dividend & Yield||N/A (N/A)|